Search the Newsreel

Is Axsome Therapeutics (AXSM) Trading Profitability for Pipeline Expansion As Revenue Outpaces Earnings?

Axsome Therapeutics (AXSM) is projected to report higher Q2 2026 revenue but lower year-over-year earnings, leading to investor scrutiny regarding its profitability amidst pipeline expansion. The company's investment narrative centers on its CNS franchise eventually translating rising revenues into sustainable profitability, with an FDA …

Axsome Therapeutics (NASDAQ:AXSM) Stock Price Down 4% After Analyst Downgrade

Axsome Therapeutics (NASDAQ:AXSM) shares dropped 4% after Mizuho lowered its price target from $310 to $306, while still maintaining an "outperform" rating. Despite missing adjusted earnings expectations with a loss of $1.26 per share, the company reported a 57.4% year-over-year revenue increase to $191.2 …

Axsome Therapeutics, Inc. (AXSM): Investor Outlook on a Biotech Stock with a 29% Potential Upside

Axsome Therapeutics (AXSM) is a biotech company focused on CNS disorders with a market capitalization of $11.22 billion. Despite negative EPS and ROE, the company has strong analyst ratings, an average target price suggesting a 29.51% upside, and robust revenue growth of 57.40%. Its …

Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for

Axsome Therapeutics (AXSM) to Announce Earnings on Monday

Axsome Therapeutics (NASDAQ: AXSM) is scheduled to announce its Q2 2026 earnings before the market opens on Monday, August 10th. Analysts anticipate a loss of $0.8921 per share and revenue of $221.1 million. Despite a previous EPS miss, revenue increased by 57.4% year-over-year, and …

Axsome Therapeutics Inc (0HKF) Q3 2025 Earnings Report - Results, Call & Slides

Axsome Therapeutics (0HKF) released its Q3 2025 earnings report, missing consensus EPS estimates with an actual EPS of -$0.94 against an expected -$0.86. However, the company beat revenue expectations, reporting $170.99M against an expected $162.67M, marking a significant 63.22% year-over-year revenue growth. The earnings …

Axsome Therapeutics, Inc. $AXSM Stock Holdings Lessened by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company reduced its stake in Axsome Therapeutics (NASDAQ:AXSM) by 12.5% in the first quarter, selling 16,791 shares. Despite this, institutional investors collectively own 81.49% of the company, with many major funds increasing their positions. Axsome Therapeutics reported revenue of $191.2 …

Sei Investments Co. Buys 22,464 Shares of Axsome Therapeutics, Inc. $AXSM

Sei Investments Co. significantly increased its stake in Axsome Therapeutics, Inc. by 47.2% in the first quarter, acquiring an additional 22,464 shares, bringing its total to 70,064 shares valued at $11.8 million. This move is part of broader institutional interest, with hedge funds and …

Mizuho Trims Price Target on Axsome Therapeutics to $306 From $310, Keeps Outperform Rating

Mizuho has adjusted its price target for Axsome Therapeutics (AXSM) to $306 from $310, while maintaining an Outperform rating on the stock. This revision comes as part of their ongoing analysis of the biopharmaceutical company.

Mizuho Issues Pessimistic Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price

Mizuho lowered its price target for Axsome Therapeutics (NASDAQ:AXSM) from $310 to $306, while maintaining an "outperform" rating, indicating a potential 40% upside. This comes after the company reported a quarterly loss of $1.26 per share, missing expectations, despite a 57.4% year-over-year revenue increase …

Axsome Therapeutics Inc (AXSM) Financial Health: Profitability & Balance Sheet Analysis

Axsome Therapeutics Inc (AXSM) has a stable financial status and high operating efficiency, with its financial score at 8.07, ranking 74 out of 155 in the Pharmaceuticals industry. The company reported a latest quarterly revenue of $191.20M, marking a 57.42% year-over-year increase, and an …

Axsome Therapeutics Inc (AXSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Axsome Therapeutics Inc (AXSM), detailing its price momentum score of 3.33, ranking 111 out of 155 in the Pharmaceuticals industry. It highlights the stock's current trading range between resistance at $251.09 and support at $219.70, suggesting suitability …

Renaissance Technologies LLC Sells 5,700 Shares of Axsome Therapeutics, Inc. $AXSM

Renaissance Technologies LLC reduced its stake in Axsome Therapeutics (NASDAQ:AXSM) by 3.4% in the first quarter, selling 5,700 shares and now owning 164,300 shares worth $27.77 million. Despite this, several other institutional investors increased their holdings, and analysts have a "Moderate Buy" rating with …

SummitTX Capital L.P. Makes New $2.59 Million Investment in Axsome Therapeutics, Inc. $AXSM

SummitTX Capital L.P. has made a new $2.59 million investment in Axsome Therapeutics, Inc. by purchasing 15,304 shares. This move is part of the broader institutional interest in Axsome Therapeutics, with other hedge funds also adjusting their positions. Despite a wider-than-expected quarterly loss, analysts …

Axsome Therapeutics Inc (AXSM) Valuation: PE, PB & Fair Value Analysis

This article analyzes the valuation of Axsome Therapeutics Inc (AXSM), noting its current valuation score of 9.71, ranking 10th in the Pharmaceuticals industry. The P/E ratio is reported at -62.84, which is significantly below its recent high and slightly above its recent low. The …

Healthcare of Ontario Pension Plan Trust Fund Invests $16.49 Million in Axsome Therapeutics, Inc. $AXSM

The Healthcare of Ontario Pension Plan Trust Fund has invested $16.49 million in Axsome Therapeutics, acquiring 97,550 shares. This comes as institutional investors now own 81.49% of the company, despite recent insider sales totaling $37.23 million. Axsome Therapeutics reported significant revenue growth of 57.4% …

BlackRock, Inc. (AXSM) reports 2.74M Axsome Therapeutics shares in Schedule 13G/A

BlackRock, Inc. has filed an Amendment No. 5 to its Schedule 13G, disclosing a beneficial ownership of 2,736,503 shares of Axsome Therapeutics, Inc. common stock, which represents a 5.3% stake. BlackRock maintains sole voting power over 2,649,256 shares and sole dispositive power over all …

Axsome Therapeutics, Inc. $AXSM Shares Sold by Orbimed Advisors LLC

Orbimed Advisors LLC reduced its stake in Axsome Therapeutics ($AXSM) by 15.5% in the first quarter, selling 39,200 shares and retaining 213,921 shares valued at $36.2 million. Despite the company reporting Q1 revenue of $191.2 million, which beat estimates, it posted an adjusted loss …

Axsome Therapeutics Inc (AXSM) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides information on Axsome Therapeutics Inc (AXSM) regarding its dividend history and stock splits. It indicates that the company has distributed a total of $0.00 in dividends over the past five years, with "No Data" available for specific dividend dates. The page …

Caxton Associates LLP Makes New Investment in Axsome Therapeutics, Inc. $AXSM

Caxton Associates LLP has made a new investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by purchasing 4,311 shares worth approximately $729,000 during the first quarter. Institutional investors now own 81.49% of the company, and analysts have a "Moderate Buy" rating with an average price target …

FDA Acceptance of AXS-12 NDA for Narcolepsy Might Change The Case For Investing In Axsome (AXSM)

Axsome Therapeutics recently received FDA acceptance for its AXS-12 New Drug Application for cataplexy in narcolepsy, with a target action date of May 1, 2027, and no advisory committee planned. This milestone is crucial for Axsome's CNS portfolio, adding a potential orphan indication and …

California Public Employees Retirement System Makes New Investment in Axsome Therapeutics, Inc. $AXSM

The California Public Employees Retirement System (CalPERS) has initiated a new investment in Axsome Therapeutics (NASDAQ:AXSM), acquiring 50,879 shares valued at approximately $8.6 million during the first quarter, representing 0.10% of the company. This comes even as insider selling was noted, with the COO …

Axsome Therapeutics (AXSM) Wins FDA NDA Acceptance, Is The Stock Fully Valued?

Axsome Therapeutics (AXSM) recently received FDA acceptance for its New Drug Application for AXS-12, an investigational treatment for cataplexy in narcolepsy, with a PDUFA date of May 1, 2027. Despite a significant 139.02% return over the past year, leading to a current share price …

AXSM|Axsome Therapeutics Inc|Price:241.000|Chg%:-0.530

Axsome Therapeutics Inc (AXSM) is trading at $241.00 with a slight decrease of 0.22%. The company, which specializes in CNS conditions, has strong fundamentals and high growth potential, with an average revenue growth of 135.96% year-on-year over the past three years. Analysts have rated …

Axsome Therapeutics, Inc. (AXSM) stock price, news, quote and history

This Yahoo Finance page provides comprehensive information on Axsome Therapeutics, Inc. (AXSM), including its current stock price, historical data, financial performance, and analyst ratings. It details the company's biotechnology focus, its commercial products for CNS disorders like Auvelity and Sunosi, and its pipeline of …

First Trust Advisors LP Increases Position in Axsome Therapeutics, Inc. $AXSM

First Trust Advisors LP significantly increased its stake in Axsome Therapeutics (NASDAQ:AXSM) by 1,230.2% in the first quarter, now owning 577,479 shares valued at $97.6 million. Despite missing EPS estimates, Axsome's revenue grew 57.4% year-over-year. Analysts maintain a "Moderate Buy" rating with an average …

Axsome Therapeutics, Inc. Revenue Breakdown – NASDAQ:AXSM

This article provides a revenue breakdown for Axsome Therapeutics, Inc. (NASDAQ: AXSM). It highlights that the company generated $633.80 million USD last year, with its "Novel Therapies for the Management of Central Nervous System Disorders" segment contributing the most at $638.50 million USD. The …

Axsome Therapeutics (AXSM) Stock is Attractive on the Back of its Key Drug

Axsome Therapeutics (AXSM) Wins FDA Acceptance For AXS 12 In Narcolepsy

Axsome Therapeutics has announced that the FDA has accepted its New Drug Application for AXS-12, a treatment for cataplexy in narcolepsy, with a PDUFA date of May 1, 2027. The FDA does not plan to hold an advisory committee meeting, which could indicate a …

AXSOME THERAPEUTICS INC : LEERINK PARTNERS RAISES TARGET PRICE TO $265 FROM $250

Leerink Partners has raised its target price for Axsome Therapeutics Inc. (AXSM) to $265 from $250. This change suggests an increased positive outlook from the financial institution regarding the company's future performance. The article is very brief and does not provide further details on …

Axsome Therapeutics (NASDAQ:AXSM) Upgraded to "Strong-Buy" at BMO Capital Markets

BMO Capital Markets upgraded Axsome Therapeutics (NASDAQ:AXSM) to a "strong-buy" rating, contributing to a consensus "Moderate Buy" rating and an average price target of $261.48 among analysts. Despite the company missing Q1 earnings estimates, its revenue increased by 57.4% year-over-year. The stock opened at …

Axsome Therapeutics (NASDAQ:AXSM) Rating Lowered to Strong Sell at Zacks Research

Zacks Research has downgraded Axsome Therapeutics (NASDAQ:AXSM) from a "hold" to a "strong sell" rating. This comes despite a broader "Moderate Buy" consensus among analysts with a price target of $261.48. The company recently reported mixed quarterly results, with an EPS of -$1.26 missing …

AXSM Initiated Coverage by BMO Capital -- Outperform Rating Assi

BMO Capital has initiated coverage on Axsome Therapeutics (AXSM) with an Outperform rating and a price target of $310.00. While GuruFocus indicates the stock is 2.1% undervalued with a GF Value™ of $226.26, its GF Score™ of 52/100 points to average performance, burdened by …

Axsome Therapeutics Inc. (AXSM) Q3 2024 Earnings Report - Results, Call & Slides

Axsome Therapeutics Inc. (AXSM) has released its Q3 2024 earnings report, showing a beat on both EPS and revenue expectations. The company reported actual EPS of -$1.34 against a consensus of -$1.38, and actual revenue of $104.76 million compared to an expected $98.37 million, …

BMO Capital Initiates Axsome Therapeutics at Outperform With $310 Price Target

BMO Capital has initiated coverage on Axsome Therapeutics with an Outperform rating and a price target of $310. This follows several recent positive developments for Axsome, including the FDA's acceptance of their New Drug Application for AXS-12 for narcolepsy treatment and the initiation of …

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from Analysts

Axsome Therapeutics (NASDAQ:AXSM) has received a "Moderate Buy" consensus rating from 21 analysts, with an average 12-month price target of $259.05. Despite reporting quarterly revenue of $191.2 million, exceeding expectations and up 57.4% year-over-year, the company posted a larger-than-expected loss of $1.26 per share, …